Stock MCRB SERES THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

All News Seres Therapeutics, Inc.

Equities

MCRB

US81750R1023

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-05-17 pm EDT 		5-day change 1st Jan Change
0.9199 USD -0.49% Intraday chart for Seres Therapeutics, Inc. -9.81% -34.29%
May. 09 Oppenheimer Adjusts Seres Therapeutics Price Target to $4 From $5, Maintains Outperform Rating MT
May. 09 Chardan Adjusts Price Target on Seres Therapeutics to $6 From $8, Keeps Buy Rating MT

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Oppenheimer Adjusts Seres Therapeutics Price Target to $4 From $5, Maintains Outperform Rating
MT
Chardan Adjusts Price Target on Seres Therapeutics to $6 From $8, Keeps Buy Rating
MT
Transcript : Seres Therapeutics, Inc., Q1 2024 Earnings Call, May 08, 2024
Seres Therapeutics: Q1 Earnings Snapshot
AQ
Seres Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates
BU
Seres Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Seres Therapeutics : Accelaration/Increase of Financial Obligation - Form 8-K
PU
Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BU
Seres Therapeutics to Announce First Quarter 2024 Financial Results and Business Update on May 8, 2024
BU
Foreign automakers eager for Chinese partners at Beijing auto show
RE
Battle for 'tech luxury' in China as EVs get smarter - and cheaper
RE
Flagship Appoints Amy O'Shea as CEO-Partner and Chief Executive Officer of Invaio Sciences
AQ
Seres Therapeutics Announces Completion of Patient Enrollment for SER-155 Phase 1B Cohort 2 Clinical Trial in Allogenic HSCT
BU
Seres Therapeutics Announces Completion of Patient Enrollment for SER-155 Phase 1B Cohort 2 Clinical Trial in Allogenic HSCT
CI
Declaration of Voting Results by Seres Therapeutics
CI
Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BU
SERES THERAPEUTICS REPORTS INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(4)
AQ
Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BU
Oppenheimer Adjusts Seres Therapeutics Price Target to $5 From $9, Maintains Outperform Rating
MT
Chardan Cuts Price Target on Seres Therapeutics to $8 From $10 on Higher Expected Sharecount Dilution, Keeps Buy Rating
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. MCRB Stock
  4. News Seres Therapeutics, Inc.
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW